Is Centrus Energy Stock a Buy Now?

Centrus Energy, the only U.S. firm licensed to produce HALEU, has started deliveries under a DOE cost-shared contract (900 kg delivered in June for ~$7.3M, about 10% of Q3 revenue) and is expected to deliver another 900 kg by June 2026, underpinning its strategic role in a domestic advanced-nuclear fuel supply chain. Despite a 225% YTD surge in 2025 and recent volatility (down ~14% over five trading days and >45% from a mid-October peak near $436), the stock trades at roughly 12x book and a forward P/E north of 60, implying that current market value is highly dependent on a smooth HALEU ramp and leaves material execution risk for investors.

Analysis

Market structure: Centrus (LEU) is functionally a toll-gate for U.S. HALEU, so successful, timely deliveries create near-term pricing power and bilateral contract leverage that benefits Centrus, reactor OEMs (BWXT) and DOE-backed integrators while pressuring non-U.S. HALEU suppliers and spot uranium sellers. Expect bilateral term-contract pricing to form around delivered-price benchmarks (mid-single to low-double-digit $/kg premium over baseline uranium) as volume ramps to low-tonne scale by 2027; incumbents without licensing lose pricing leverage.

Risk assessment: Tail risks include a DOE funding pullback, an NRC-adverse finding, or a single-site operational halt — any of which could halve equity value within days and delay revenue recognition by 12–24 months. Near term (days–weeks) watch share-price volatility and stop-out thresholds; over 3–12 months the key risk is execution cadence against the June-2026 900 kg milestone; through 2–5 years demand risk centers on slower advanced-reactor adoption and competing supply entrants.

Trade implications: If you believe the ramp, size exposure small and hedge: prefer a calibrated long via buy-call-spread or stock + protective-put rather than naked stock. Relative-value: long LEU vs short CCJ (Cameco) or URA can capture a re-rating if domestic HALEU carries a premium; rotate 1–3% portfolio from broad uranium ETFs into supply-chain winners (LEU, BWXT).

Contrarian angles: Consensus assumes a smooth DOE-backed scale-up — markets underprice operational and regulatory binary risk, yet overpay (forward P/E >60) for a single supplier story. Historical analogies: early biotech/defense production ramps show stepwise re-rating on milestones; a missed milestone typically resets valuation by 40–70%, so price in success only with milestone hedges and staged sizing.

Key Decisions for Investors

• Establish a tactical 1.5% long position in LEU now sized to portfolio, hedge with a 6–9 month 25% OTM protective put or equivalent cost-capped collar; set hard stop-loss at -25% and take-profit target at +50% (reassess at June 2026 delivery milestone).
• Implement a pair trade: go long LEU 1.5% and short CCJ (Cameco) 1.0% notional to express view that domestic HALEU premium will out-earn conventional uranium miners if deliveries hit by H1 2026; rebalance or unwind within 6–12 months or on delivery miss.
• Buy a Jan 2027 LEU call spread (buy 30–50% OTM, sell 80–100% OTM) sized to ≤2% portfolio notional to play the June 2026 and Jan 2027 delivery cadence while capping premium; leg into position by Mar–May 2026 if DOE progress reports show on-schedule production.
• Reduce broad uranium ETF (e.g., URA) exposure by 1–2% and redeploy into identified supply-chain names (LEU, BWXT) and add liquid event-driven protection: monitor DOE contract milestone reports, NRC licensing updates, and any safety incident notices on a 30–90 day cadence — only add to LEU after confirmed on-schedule second-delivery by Mar 2026.